Nascimben O, Schiavon F, Pagan V, Giannico S, Agazia L, Turcato G, Polico R, Idi M B, Stea L, Conte G
Divisione di Radioterapia, dale Civile Umberto I, Mestre VE.
Radiol Med. 1988 May;75(5):534-9.
The results are reported of a multidisciplinary diagnostic and therapeutic program applied to 381 patients with lung carcinoma from 1983 through 1985 at Mestre General Hospital. Cytologic and/or histologic diagnosis was established in 95% and staging accomplished in 96% of the patients. One-hundred-twenty-nine patients with non-small cell cancer were primarily treated by surgery (lobectomy or pneumonectomy); 3-year survival of this group was 48%. Of the 45 patients with pN1 or pN2 disease, 23 were treated with postoperative adjunctive mediastinal radiotherapy (50Gy/25 F/5Wk); however, survival showed no significant difference in the two groups. Ninety-seven inoperable patients were treated by radiotherapy alone; among those receiving doses of 50-60 Gy in 5 to 6 weeks, 3-year survival was 10%. Chemotherapy (CAMP), used in 23 cases (22 stage IV, 1 stage III), showed no improvement in survival, as compared with a similar series of patients submitted to symptomatic treatment alone. Of the 27 patients affected by small-cell carcinoma, 14 were treated with an aggressive radiochemotherapy protocol and 13 with palliative radiotherapy or low-dose chemotherapy: median survival in the two groups was respectively 45 and 60 weeks. Our study demonstrates the clinical feasibility of interdisciplinary programs routinely applied to a large population of lung cancer patients, and confirms its rationale in terms of early diagnosis, improved staging, and adequate treatment.
本文报告了1983年至1985年期间在梅斯特雷综合医院对381例肺癌患者实施的多学科诊断与治疗方案的结果。95%的患者确立了细胞学和/或组织学诊断,96%的患者完成了分期。129例非小细胞癌患者主要接受手术治疗(肺叶切除术或全肺切除术);该组患者的3年生存率为48%。在45例pN1或pN2期疾病患者中,23例接受了术后纵隔辅助放疗(50Gy/25次/5周);然而,两组生存率无显著差异。97例无法手术的患者仅接受放疗;在5至6周内接受50 - 60Gy剂量放疗的患者中,3年生存率为10%。23例患者(22例IV期,1例III期)接受化疗(CAMP方案),与仅接受对症治疗的类似患者系列相比,生存率并无改善。在27例小细胞癌患者中,14例接受了积极的放化疗方案,13例接受了姑息性放疗或低剂量化疗:两组的中位生存期分别为45周和60周。我们的研究证明了常规应用于大量肺癌患者的跨学科方案的临床可行性,并在早期诊断、改善分期和充分治疗方面证实了其合理性。